These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26581940)

  • 41. [Information on the risk of drugs in pregnancy: New regulation of the Food and Drug Administration].
    García Caeiro ÁL; Rey Liste MT; Ventosa Rial JJ; Alonso Fachado A
    Aten Primaria; 2017 Dec; 49(10):622-623. PubMed ID: 28844480
    [No Abstract]   [Full Text] [Related]  

  • 42. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Klafehn CW
    Hosp Pharm; 2016 Sep; 51(8):688-691. PubMed ID: 27698510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The FDA Revises Boxed Warning For Fluoroquinolones-Again.
    Aschenbrenner DS
    Am J Nurs; 2016 Sep; 116(9):22-3. PubMed ID: 27560334
    [No Abstract]   [Full Text] [Related]  

  • 44. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
    Cook DM; Gurugubelli RK; Bero LA
    Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019.
    Guadamuz JS; Qato DM; Alexander GC
    JAMA; 2020 Jul; 324(3):299-301. PubMed ID: 32692379
    [No Abstract]   [Full Text] [Related]  

  • 46. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Rose B
    Hosp Pharm; 2016 Jun; 51(6):491-2. PubMed ID: 27354752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety-related drug labeling changes approved by FDA.
    White GG
    J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
    [No Abstract]   [Full Text] [Related]  

  • 48. The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality?
    Vladutiu GD
    Mol Genet Metab; 2008 Jan; 93(1):1-4. PubMed ID: 18054511
    [No Abstract]   [Full Text] [Related]  

  • 49. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
    Matlock A; Allan N; Wills B; Kang C; Leikin JB
    Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, July-September 2016.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Dec; 73(23):e664-e666. PubMed ID: 27864210
    [No Abstract]   [Full Text] [Related]  

  • 51. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, July-September 2016.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Dec; 73(23):1903. PubMed ID: 27864195
    [No Abstract]   [Full Text] [Related]  

  • 52. Summaries of Safety Labeling Changes Approved By FDA- Boxed Warnings Highlights July-September 2017.
    Hosp Pharm; 2018 Feb; 53(1):18-24. PubMed ID: 29434382
    [No Abstract]   [Full Text] [Related]  

  • 53. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2017.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2017 Dec; 74(23):1934. PubMed ID: 29167132
    [No Abstract]   [Full Text] [Related]  

  • 54. US consumer group criticizes proposal to allow drug makers to challenge safety information.
    McCarthy M
    BMJ; 2015 Mar; 350():h1514. PubMed ID: 25784706
    [No Abstract]   [Full Text] [Related]  

  • 55. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2018.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2018 Dec; 75(23):1850. PubMed ID: 30463860
    [No Abstract]   [Full Text] [Related]  

  • 56. Medication use in pregnancy and the pregnancy and lactation labeling rule.
    Sahin L; Nallani SC; Tassinari MS
    Clin Pharmacol Ther; 2016 Jul; 100(1):23-5. PubMed ID: 27082701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
    Greiwe J; Honsinger R; Hvisdas C; Chu DK; Lang DM; Nicklas R; Apter AJ
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3057-3063. PubMed ID: 36064185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2019.
    Am J Health Syst Pharm; 2020 Jan; 77(2):e1-e3. PubMed ID: 31804674
    [No Abstract]   [Full Text] [Related]  

  • 59. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2019.
    Am J Health Syst Pharm; 2020 Jan; 77(2):71-72. PubMed ID: 31764953
    [No Abstract]   [Full Text] [Related]  

  • 60. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.